Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.64 |
| ▸ | RAF1 | P04049 | 10/20 | 0.64 |
| ▸ | FLT4 | P35916 | 6/20 | 0.52 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | KIF5B | P33176 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13680220 | 0.90 | RAF1 (0.62) | BRAFRAF1FLT4CSF1RPDGFRB | |
| SCHEMBL1012845 | 0.86 | BRAF (0.62) | BRAFRAF1FLT4CSF1RPDGFRB | |
| SCHEMBL19258207 | 0.86 | RAF1 (0.64) | BRAFRAF1FLT4PDGFRBFGFR2 | |
| SCHEMBL17278100 | 0.85 | BRAF (0.70) | BRAFRAF1FLT4KDRFLT1 | |
| SCHEMBL13680227 | 0.83 | BRAF (0.64) | BRAFRAF1KDRRETKIF5B | |
| SCHEMBL1015360 | 0.80 | KDM1A (0.66) | BRAFRAF1FLT4CSF1RPDGFRB | |
| SCHEMBL1012448 | 0.80 | KDR (0.73) | BRAFRAF1FLT4CSF1RPDGFRB | |
| SCHEMBL19258467 | 0.80 | AURKA (0.62) | BRAFRAF1FLT4CSF1RPDGFRB | |
| Ammonia Solution, Strong SCHEMBL1010619 | 0.79 | KDM1A (0.65) | BRAFRAF1FLT4CSF1RPDGFRB | |
| SCHEMBL13680219 | 0.79 | RAF1 (0.60) | BRAFRAF1FLT4CSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |